| 1. |
喬海泉. Whipple 手術胰瘺的探索與思考. 中華普通外科學文獻(電子版), 2015, 9(3): 179-181.
|
| 2. |
Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase Ⅲ trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 2007, 25(15): 1960-1966.
|
| 3. |
Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 2015, 518(7540): 495-501.
|
| 4. |
Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 2016, 531(7592): 47-52.
|
| 5. |
Xu HX, Liu L, Xiang JF, et al. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma. Surgery, 2017, 161(2): 373-384.
|
| 6. |
Luo G, Xiao Z, Long J, et al. CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer. J Gastrointest Surg, 2013, 17(12): 2092-2098.
|
| 7. |
Liu L, Xu HX, Wang WQ, et al. Serum CA125 is a novel predictive marker for pancreatic cancer metastasis and correlates with the metastasis-associated burden. Oncotarget, 2016, 7(5): 5943-5956.
|
| 8. |
Liu L, Xu H, Wang W, et al. A preoperative serum signature of CEA+/CA125+/CA19-9≥1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Int J Cancer, 2015, 136(9): 2216-2227.
|
| 9. |
Luo G, Liu C, Guo M, et al. Potential biomarkers in Lewis negative patients with pancreatic cancer. Ann Surg, 2017, 265(4): 800-805.
|
| 10. |
Luo G, Liu C, Guo M, et al. CA19-9-low&Lewis(+) pancreatic cancer: a unique subtype. Cancer Lett, 2017, 385: 46-50.
|
